Overexpression of inflammatory biomarkers is associated with subsequent lung function abnormalities in patients recovered from severe COVID-19, finds a study published in BMCPulmMed
]. Importantly, we did not find evidence of abnormal biomarkers for coagulation dysfunction in patients with reduced D. These findings suggest that although plausible physiologic abnormalities that could contribute to low Dhave been identified in COVID-19, further work is required to uncover the precise mechanisms for development of persistent impaired oxygen transfer.
Limitations of our study include that we were unable to measure specific inflammatory cytokines in our study. Due to resource constraints, it was not possible to measure Din all patients. We additionally excluded hospitalized patients that did not have measurement of the biomarkers included in our study, which may introduce potential bias to our results.
In conclusion, our results demonstrate that biomarkers of increased inflammation, organ dysfunction, and altered coagulation were related to a restrictive spirometric pattern and impaired diffusing capacity; however, biomarkers included in our study explained a small proportion of the variance in FVC or D. Uncovering a potential causal relationship between increased inflammation and impaired lung function may provide a useful therapeutic target in the follow-up of patients with severe COVID-19.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
The role of pulmonary dysfunction and COVID-19 severity in the development of Long COVIDThe role of pulmonary dysfunction and COVID-19 severity in the development of Long COVID medrxivpreprint covid COVID19 SARSCoV2 longCOVID longcovid
Read more »
Renal interferon-inducible protein 16 expression is associated with disease activity and prognosis in lupus nephritis - Arthritis Research & TherapyBackground Lupus nephritis (LN) is one of the most severe complications of systemic lupus erythematosus (SLE). However, the current management of LN remains unsatisfactory due to sneaky symptoms during early stages and lack of reliable predictors of disease progression. Methods Bioinformatics and machine learning algorithms were initially used to explore the potential biomarkers for LN development. Identified biomarker expression was evaluated by immunohistochemistry (IHC) and multiplex immunofluorescence (IF) in 104 LN patients, 12 diabetic kidney disease (DKD) patients, 12 minimal change disease (MCD) patients, 12 IgA nephropathy (IgAN) patients and 14 normal controls (NC). The association of biomarker expression with clinicopathologic indices and prognosis was analyzed. Gene Set Enrichment Analysis (GSEA) and Gene Set Variation Analysis (GSVA) were utilized to explore potential mechanisms. Results Interferon-inducible protein 16 (IFI16) was identified as a potential biomarker for LN. IFI16 was highly expressed in the kidneys of LN patients compared to those with MCD, DKD, IgAN or NC. IFI16 co-localized with certain renal and inflammatory cells. Glomerular IFI16 expression was correlated with pathological activity indices of LN, while tubulointerstitial IFI16 expression was correlated with pathological chronicity indices. Renal IFI16 expression was positively associated with systemic lupus erythematosus disease activity index (SLEDAI) and serum creatinine while negatively related to baseline eGFR and serum complement C3. Additionally, higher IFI16 expression was closely related to poorer prognosis of LN patients. GSEA and GSVA suggested that IFI16 expression was involved in adaptive immune-related processes of LN. Conclusion Renal IFI16 expression is a potential biomarker for disease activity and clinical prognosis in LN patients. Renal IFI16 levels may be used to shed light on predicting the renal response and develop precise therapy for LN.
Read more »
Combined oral antibiotics and intrauterine perfusion can improve in vitro fertilization and embryo transfer pregnancy outcomes in patients with chronic endometritis and repeated embryo implantation failure - BMC Women's HealthBackground The aim of this retrospective study was to investigate whether oral antibiotics (doxycycline and metronidazole) combined with intrauterine perfusion (gentamicin and dexamethasone) are beneficial for patients with repeated implantation failure (RIF) and chronic endometritis (CE) to improve clinical pregnancy outcomes. Methods Patients with RIF and CE were diagnosed using hysteroscopy and histology together. A total of 42 patients were enrolled in the study. All patients received oral antibiotics (doxycycline combined with metronidazole) and 22 patients underwent intrauterine perfusion (gentamicin combined with dexamethasone) immediately after the end of oral antibiotic therapy. Pregnancy outcomes were evaluated during the first in vitro fertilization (IVF) and embryo transfer (ET) cycle. Results For the first D3 ET after treatment with oral antibiotics (doxycycline and metronidazole) combined with intrauterine perfusion (gentamicin and dexamethasone), higher embryo implantation rate (30.95% vs. 26.67%, P = 0.0308), clinical pregnancy rate (30% vs. 50%, P | 0.001), live birth rate (33.33% vs. 45.45%, P | 0.0001). No fetal malformations or ectopic pregnancies were observed. Conclusion We report oral antibiotics (doxycycline and metronidazole) combined with intrauterine perfusion (gentamicin and dexamethasone) as a novel treatment for CE to improve the outcomes of successful pregnancy compared with those of oral antibiotics alone.
Read more »
How cancer patients receive the most modern care in buildings that are 'not fit for purpose'Cancer treatment is carried out in a building that opened in 1839 in the Royal Berkshire Hospital - with waiting patients having to be evacuated after rain flooded through the ceiling.
Read more »
Staff and patients in Nottingham celebrate NHS 75th anniversaryTwo giant birthday cards have been presented to Nottingham's hospitals, to celebrate the 75th anniversary, on July 5
Read more »
Muckamore Abbey Hospital set to shut in June 2024The planned hospital closure will have no bearing on the criminal investigation into patient abuse nor the work of the Muckamore public inquiry, says Department of Health:
Read more »